CN103333349A - Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof - Google Patents
Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof Download PDFInfo
- Publication number
- CN103333349A CN103333349A CN2013102640629A CN201310264062A CN103333349A CN 103333349 A CN103333349 A CN 103333349A CN 2013102640629 A CN2013102640629 A CN 2013102640629A CN 201310264062 A CN201310264062 A CN 201310264062A CN 103333349 A CN103333349 A CN 103333349A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- collagen protein
- preparation
- collagen
- linking agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001436 collagen Polymers 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000002131 composite material Substances 0.000 title claims abstract description 20
- 238000002347 injection Methods 0.000 title claims abstract description 19
- 239000007924 injection Substances 0.000 title claims abstract description 19
- 239000000017 hydrogel Substances 0.000 title abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 52
- 108010035532 Collagen Proteins 0.000 claims abstract description 52
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 29
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 27
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 238000006243 chemical reaction Methods 0.000 claims abstract description 20
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 18
- 238000003756 stirring Methods 0.000 claims abstract description 16
- 238000004140 cleaning Methods 0.000 claims abstract description 6
- 238000000227 grinding Methods 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 239000004971 Cross linker Substances 0.000 claims description 18
- 239000003637 basic solution Substances 0.000 claims description 15
- 239000002504 physiological saline solution Substances 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 230000035484 reaction time Effects 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- LFKLPJRVSHJZPL-UHFFFAOYSA-N 1,2:7,8-diepoxyoctane Chemical compound C1OC1CCCCC1CO1 LFKLPJRVSHJZPL-UHFFFAOYSA-N 0.000 claims description 4
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical group CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 claims description 4
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 4
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 4
- 238000012407 engineering method Methods 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- WTYYGFLRBWMFRY-UHFFFAOYSA-N 2-[6-(oxiran-2-ylmethoxy)hexoxymethyl]oxirane Chemical compound C1OC1COCCCCCCOCC1CO1 WTYYGFLRBWMFRY-UHFFFAOYSA-N 0.000 claims description 3
- 239000000499 gel Substances 0.000 abstract description 21
- 239000000463 material Substances 0.000 abstract description 9
- 230000010261 cell growth Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000021164 cell adhesion Effects 0.000 abstract description 3
- 210000004872 soft tissue Anatomy 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 238000011049 filling Methods 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 239000003431 cross linking reagent Substances 0.000 abstract 3
- 229920002385 Sodium hyaluronate Polymers 0.000 abstract 1
- 239000012670 alkaline solution Substances 0.000 abstract 1
- 229940010747 sodium hyaluronate Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000000418 atomic force spectrum Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002118 epoxides Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- -1 glycidol ethers Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000001507 sample dispersion Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
Images
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention relates to hyaluronic acid-collagen composite hydrogel for injection and a preparation method thereof. Current hyaluronic acid cross-linked hydrogel cannot remove toxicity residue through cleaning in a preparation process, thus having a potential safety hazard. The preparation method comprises the steps of mixing and dissolving sodium hyaluronate and collagen in an alkaline solution, uniformly stirring and adding a cross-linking agent to a reaction system, uniformly mixing and reacting to obtain gel in a block form, processing the gel to remove residual cross-linking agent, and grinding to obtain granular hydrogel. Due to introduction of the collagen, the prepared hydrogel is more ideal, and low in residue of the cross-linking agent and relatively low in damage to a living organism; the collagen can improve the mechanical strength of the hydrogel, and bring about positive influence to cell adhesion and cell growth promotion property of the product, so that the hydrogel, as a soft tissue filling material, shows a greater advantage.
Description
Technical field
The present invention relates to a kind of hydrogel, be specifically related to a kind of injection hyaluronic acid-collagen protein composite aquogel and preparation method thereof.
Background technology
Hyaluronic acid is a kind of acidic mucopolysaccharide, claims uronic acid, Hyaluronic Acid again, the natural polymers of being made up of two D-of disaccharide unit glucuronic acids and N-acetyl-glucosamine.Its moisture of molecule portability more than 500 times is the good composition of preserving moisture of a kind of effect, is called as desirable natural moisturizing factor.Hyaluronic acid, its esters and derivative have good Bioabsorbable, biocompatibility, visco-elasticity and water-retentivity, therefore are widely used in beauty treatment, medicine and other fields.Clinically, hyaluronic acid can be used for ophthalmologic operation, prevention of postoperative adhesion in the surgical operation, aspects such as the healing of promotion wound and beauty and shaping, some medicines are attached to the effect that the compound that forms on the hyaluronic acid can also be brought into play medicine control slowly-releasing, thereby reach the purpose that medicine timing and fixed point discharge, but because hyaluronic acid exists degradation speed fast, defectives such as physical strength is lower, and limited its range of application, therefore in actual applications, often make in the hyaluronan molecule by method such as cross-linking modified or the crosslinked preparation of intermolecular generation becomes hyaluronic acid gel, thereby prolong its action time in vivo.
About the existing patent report of the preparation of cross-linking hyaluronic acid hydrogel.Patent CN 101538377 A disclose a kind of preparation method of cross-linked hyaluronic acid gel.In this invention, adopt 1,4-butanediol diglycidyl ether as linking agent under alkaline condition with hyaluronic acid in hydroxyl react, remove unreacted linking agent and prepare product thereby clean with physiological balance liquid again.But in reaction process, the butanediol diglycidyl ether that has has only an epoxide group to participate in reaction, and these linking agents can't be removed by cleaning, therefore also can have the problem of residual toxicity.
Patent CN 101724164 B disclose a kind of method of making cross-linked-hyaluronic acid.In this method, make hyaluronic acid solution under 10-30 ℃, carry out crosslinking reaction and surpass 48h.The crosslinking reaction of carrying out under this low reaction temperatures, formed cross-linked-hyaluronic acid can be not termination reaction after making linking agent be consumed to rational content because of the quick deterioration of the hydrolytic action of alkali.Do not remove residual BDDE in the method, can have potential safety hazard.
Collagen protein is a kind of macromolecule protein, generally is white in color, opaque fibrous.It is one of main component of human body composition structure, also is the necessary material of delaying human body caducity, is distributed in widely in skin, bone, cartilage, muscle, joint and the hair tissue of human body, can play the function that supports organ, protection human body and reparation.Human-like Collagen is that the mRNA reverse transcription with human collagen albumen becomes cDNA, and the fragment gene after enzyme is cut is reconstituted in the E.coli(intestinal bacteria) in, a kind of high-molecular biologic albumen of producing through high density fermentation, separation, renaturation, purifying process.It has good bioresorbable, cell adhesion and biocompatibility, and can obviously promote the cell growth, therefore is fit to very much be applied to aspects such as medical science, shaping.
The epoxy compounds class is widely used in the preparation of hyaluronic acid derivatives as linking agent.It can with hyaluronan molecule in hydroxyl and carboxyl react and form ehter bond and ester bond, the present invention is mixed into collagen protein in reaction system after, epoxy compounds also can with collagen protein in hydroxyl and carboxyl reaction, and also can form the parahelium group with amino reaction wherein, therefore, make that the epoxy compounds reaction is more thorough, formed three-dimensional structure is finer and close, can effectively promote the mechanical property of product water gel.
Summary of the invention
The purpose of this invention is to provide that a kind of use is safer, the better injection hyaluronic acid of slow releasing function-collagen protein composite aquogel and preparation method thereof.
The technical solution adopted in the present invention is:
The preparation method of a kind of injection hyaluronic acid-collagen protein composite aquogel is characterized in that:
Realized by following steps:
Step 1: hyaluronate sodium is dissolved in the basic solution, stirs it is dissolved fully, make that hyaluronic mass concentration is 6%-20% in the mixing solutions;
Step 2: add collagen protein, making the mass concentration of collagen protein in the mixing solutions is 1-6%, stirs;
Step 3: add linking agent, the mass concentration that makes linking agent in the mixing solutions is 1-10%, temperature of reaction 30-60 ℃, and reaction times 1-14 hour;
Step 4: remove residual cross-linker;
Step 5: the product that obtains in physiological saline balance 3-6 hour;
Step 6: the centrifugal physiological saline of removing, products therefrom is pulverized the formation particle.
In the step 1, the molecular weight of hyaluronate sodium is 50-300 ten thousand.
In the step 1, basic solution is selected from sodium hydroxide, potassium hydroxide, sodium carbonate solution, and the molecular volume mark is 0.02-2 mol/L.
In the step 2, collagen protein is selected from total length collagen protein, collagen polypeptide, the gelatin that extracts from animal tissues; Or the recombined collagen, the Human-like Collagen that adopt gene engineering method to produce.
In the step 3, linking agent is selected from ethylene glycol diglycidylether, 1,4-butanediol diglycidyl ether, glycol ether diglycidylether, polyethyleneglycol diglycidylether, polypropylene glycol diglycidyl ether, 1,6-hexanediol diglycidyl ether, 1,2,7,8-diepoxy octane, divinylsulfone.
In the step 4, the method for removing residual cross-linker is selected from washing, organic solvent cleaning, High Temperature High Pressure distillation.
In the step 6, pulverization process is selected from extruding, grinding, cutting mode.
Injection hyaluronic acid-collagen protein composite aquogel that a kind of preparation method as described makes.
The present invention has the following advantages:
It is raw material that the present invention adopts hyaluronate sodium and collagen protein, and the Racemic glycidol ethers is that linking agent prepares hydrogel.There is the problem that degradation speed is too fast, physical strength is low in simple use hyaluronate sodium when preparing hydrogel, can not satisfy clinical application fully.Therefore we introduce collagen protein and prepare more desirable hydrogel.The linking agent residual quantity is low in the product that obtains, less to the organism infringement, and collagen protein can improve the physical strength of hydrogel, and to cell adhesion and the promoting growth of cell generation active influence of product, thereby make this hydrogel show bigger advantage as soft tissue filling material.
Description of drawings
Fig. 1 is that hydrogel is respectively at vitro culture 1, relative cell survival rate after 3,5 days.
Fig. 2 is the compression displacement of hydrogel and the relation curve between the compressive load.
Embodiment
The present invention will be described in detail below in conjunction with embodiment.
The purpose of this invention is to provide a kind of injection hyaluronic acid-collagen protein composite aquogel and preparation method, hyaluronate sodium mixed with certain proportion with collagen protein be dissolved in the basic solution, in reaction system, add glycidyl ether after stirring, mix under certain temperature and react, obtain block gel, through cleaning or distilling and remove residual cross-linker, homogenizing makes it become the particulate state hydrogel.
The preparation method of a kind of injection hyaluronic acid-collagen protein composite aquogel involved in the present invention is characterized in that:
Realized by following steps:
Step 1: hyaluronate sodium is dissolved in the basic solution, stirs it is dissolved fully, make that hyaluronic mass concentration is 6%-20% in the mixing solutions.
The molecular weight of hyaluronate sodium is 50-300 ten thousand; Basic solution is selected from sodium hydroxide, potassium hydroxide, sodium carbonate solution, and the molecular volume mark is 0.02-2 mol/L.
Step 2: add collagen protein, making the mass concentration of collagen protein in the mixing solutions is 1-6%, stirs.
Collagen protein is selected from total length collagen protein, collagen polypeptide, the gelatin that extracts from animal tissues; Or the recombined collagen, the Human-like Collagen that adopt gene engineering method to produce.
Step 3: add linking agent, the mass concentration that makes linking agent in the mixing solutions is 1-10%, temperature of reaction 30-60 ℃, and reaction times 1-14 hour.
Linking agent is selected from ethylene glycol diglycidylether, 1,4-butanediol diglycidyl ether, glycol ether diglycidylether, polyethyleneglycol diglycidylether, polypropylene glycol diglycidyl ether, 1,6-hexanediol diglycidyl ether, 1,2,7,8-diepoxy octane, divinylsulfone.
Step 4: remove residual cross-linker.
The method of removing residual cross-linker is selected from washing, organic solvent cleans (ethanol, acetone etc.), High Temperature High Pressure distillation, but also several different methods is used.
Step 5: the product that obtains in physiological saline balance 3-6 hour.
Step 6: the centrifugal physiological saline of removing, products therefrom is pulverized the formation particle.
Pulverization process is selected from extruding, grinding, cutting mode.
Embodiment 1:
Step 1: hyaluronate sodium is dissolved in the basic solution, stirs it is dissolved fully, make that hyaluronic mass concentration is 6% in the mixing solutions.
The molecular weight of hyaluronate sodium is 50-300 ten thousand; Basic solution is chosen sodium hydroxide solution, and the molecular volume mark is 0.02mol/L.
Step 2: add collagen protein, making the mass concentration of collagen protein in the mixing solutions is 1%, stirs.
Collagen protein is chosen the total length collagen protein that extracts from animal tissues.
Step 3: add linking agent, the mass concentration that makes linking agent in the mixing solutions is 1%, 30 ℃ of temperature of reaction, 1 hour reaction times.
Linking agent is selected from ethylene glycol diglycidylether, 1, the 4-butanediol diglycidyl ether.
Step 4: remove residual cross-linker.
Remove the method for residual cross-linker and choose washing.
Step 5: the product that obtains balance 3 hours in physiological saline.
Step 6: the centrifugal physiological saline of removing, products therefrom is pulverized the formation particle.
Pulverization process is chosen fashion of extrusion.
Embodiment 2:
Step 1: hyaluronate sodium is dissolved in the basic solution, stirs it is dissolved fully, make that hyaluronic mass concentration is 10% in the mixing solutions.
The molecular weight of hyaluronate sodium is 50-300 ten thousand; Basic solution is chosen potassium hydroxide solution, and the molecular volume mark is 0.5 mol/L.
Step 2: add collagen protein, making the mass concentration of collagen protein in the mixing solutions is 2%, stirs.
Collagen protein is chosen the collagen polypeptide that extracts from animal tissues.
Step 3: add linking agent, the mass concentration that makes linking agent in the mixing solutions is 4%, 40 ℃ of temperature of reaction, 5 hours reaction times.
Linking agent is selected from glycol ether diglycidylether, polyethyleneglycol diglycidylether.
Step 4: remove residual cross-linker.
Remove the method for residual cross-linker and choose organic solvent cleaning (ethanol, acetone etc.).
Step 5: the product that obtains balance 4 hours in physiological saline.
Step 6: the centrifugal physiological saline of removing, products therefrom is pulverized the formation particle.
Pulverization process is chosen grinding.
Embodiment 3:
Step 1: hyaluronate sodium is dissolved in the basic solution, stirs it is dissolved fully, make that hyaluronic mass concentration is 15% in the mixing solutions.
The molecular weight of hyaluronate sodium is 50-300 ten thousand; Basic solution is chosen sodium carbonate solution, and the molecular volume mark is 1 mol/L.
Step 2: add collagen protein, making the mass concentration of collagen protein in the mixing solutions is 4%, stirs.
Collagen protein is chosen the gelatin that extracts from animal tissues.
Step 3: add linking agent, the mass concentration that makes linking agent in the mixing solutions is 7%, 50 ℃ of temperature of reaction, 10 hours reaction times.
Linking agent is selected from polypropylene glycol diglycidyl ether, 1, the 6-hexanediol diglycidyl ether.
Step 4: remove residual cross-linker.
Remove the method for residual cross-linker and choose the High Temperature High Pressure distillation.
Step 5: the product that obtains balance 5 hours in physiological saline.
Step 6: the centrifugal physiological saline of removing, products therefrom is pulverized the formation particle.
Pulverization process is chosen cutting mode.
Embodiment 4:
Step 1: hyaluronate sodium is dissolved in the basic solution, stirs it is dissolved fully, make that hyaluronic mass concentration is 20% in the mixing solutions.
The molecular weight of hyaluronate sodium is 50-300 ten thousand; Basic solution is chosen sodium carbonate solution, and the molecular volume mark is 2 mol/L.
Step 2: add collagen protein, making the mass concentration of collagen protein in the mixing solutions is 6%, stirs.
Collagen protein is chosen recombined collagen, the Human-like Collagen that adopts gene engineering method to produce.
Step 3: add linking agent, the mass concentration that makes linking agent in the mixing solutions is 10%, 60 ℃ of temperature of reaction, 14 hours reaction times.
Linking agent is selected from 1,2,7,8-diepoxy octane, divinylsulfone.
Step 4: remove residual cross-linker.
The method of removing residual cross-linker adopts washing, organic solvent to clean the cooperation of several different methods in (ethanol, acetone etc.), the High Temperature High Pressure distillation.
Step 5: the product that obtains balance 6 hours in physiological saline.
Step 6: the centrifugal physiological saline of removing, products therefrom is pulverized the formation particle.
Pulverization process adopts the cooperation of several different methods in extruding, grinding, the cutting mode.
Below be the correlated performance test of injection water gel involved in the present invention:
1, the cytotoxicity of material detects
Bhk cell is the hamster nephrocyte, and material is analyzed by novel cell propagation and cytotoxicity detection kit (cck-8) the growth of this cell and the influence of propagation.Its ultimate principle is that the succinodehydrogenase in the viable cell plastosome can be with 2-(2-methoxyl group-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonic acid benzene)-2H-tetrazolium list sodium salt (WST-8) is reduced to water miscible yellow De Jia Za product, cell proliferation is more fast more many, color is more dark, cytotoxicity is more big, color is more shallow, and the depth of color is directly proportional with the quantity of viable cell, thereby can obtain the propagation situation of cell.
With attached cell with tryptic digestion after, make cell suspending liquid with nutrient solution, according to every hole 10
3-10
4Individual cell inoculation is in 96 orifice plates, and every hole 100 μ L, and orifice plate placed cell culture incubator cultivate 1d and make cell attachment.
Material is immersed in the nutrient solution behind 37 ℃ of following lixiviate 72h, cultivates attached cell with vat liquor, with the hole that adds normal nutrient solution in contrast.Behind 1,3,5d, every hole adds 10 μ L cck-8, continues to cultivate after 4 hours, uses microplate reader to measure absorbancy at the 450nm place.
After each was organized the OD value and gets average, it was as follows to calculate the cell relative survival rate:
According to ISO10993-1.1997 and standard GB/T16886.5-2003, the cytotoxicity grade of hyaluronic acid derivatives and hyaluronic acid-collagen protein plural gel is 0 grade, and after cultivating 5 days, the promoting growth of cell effect of composite aquogel is obviously good than hyaluronic acid derivatives.By contrast and experiment, we can draw: compound after the collagen protein on the hyaluronic acid derivatives basis, and the growth of cell be can effectively promote, thereby the cell growth of this material and the promoter action of propagation proved.Therefore, the vat liquor that experimental results show that two kinds of hydrogels has promoter action to the growth of cell, makes the relative survival rate of cell increase with incubation time, illustrates that this hydrogel does not have significant cytotoxicity, and have excellent biological compatibility, meet the requirement that biomaterial is used.
2, the syringeability of material
Sample is filled in the 1mL syringe, during experiment, installs the 27G entry needle, simulate actual service condition.Promote pushing ram with constant driving velocity 30mm/min, the sample in the syringe is pushed out via syringe needle.Obtain the pushing force curve.
As seen from the figure, in certain compression displacement, the compressive load variation range of injectable hyaluronic acid--Human-like Collagen composite aquogel is between 5-8N, the rangeability of compressive load is very little, the high low head that pushing force is described is less, show that sample dispersion is even, injection comparatively easily and convenient, and the grain diameter of explanation injectable hyaluronic acid-Human-like Collagen composite aquogel homogeneous comparatively.
3, the size distribution of gel
Get jel product 0.5g, add 0.2% toluidine blue-ethanolic soln dyeing 1min, then centrifuging and taking precipitates, add 1mL distilled water and leave standstill 1min, abandon supernatant liquor after centrifugal, add 95% ethanol 5mL color separation 5min, the more centrifugal ethanol of abandoning, add the dilution of 1mL physiological saline, under 100 times of opticmicroscopes, observe counting, measure particle diameter.
4, hyaluronic acid contents is measured in the gel
Get product 0.5g, add 4.6M HCl hydrolysis 2h in 70 ℃ of water-baths, the solution constant volume adopts the carbazole method to measure wherein glucuronic acid content, thereby can obtain hyaluronic acid contents (A) in the 100mL volumetric flask.
5, the resistance to enzymolysis performance measurement of gel
Get gel 0.5g, add 3mg/mL hyaluronic acid enzyme solution 0.5mL, 37 ℃ of following hydrolysis 15h, 0.22 get 0.5mL filtrate behind the μ m membrane filtration, be settled to 50mL, the carbazole method is measured wherein uronic acid concentration, thereby obtain hyaluronic acid contents (B), the resistance to enzymolysis performance B/A value representation of gel.The results are shown in Table 1.
Table 1 gel determination result
By data in the table as can be seen, under same processing condition, preparing resulting hyaluronic acid derivatives and hyaluronic acid-collagen protein plural gel size distribution is more or less the same, but hyaluronic acid contents is different in the product, and the resistance to enzymolysis performance of hyaluronic acid derivatives is obviously poor than hyaluronic acid-collagen protein plural gel, illustrates that hyaluronic acid-collagen protein plural gel retention time in vivo can obviously prolong.
6, the residual mensuration of linking agent in the jel product
Adopt the residual quantity of linking agent in the fluorescence spectrophotometry gel, the results are shown in Table 2.
The residual quantity of linking agent in table 2 gel
Because linking agent has low toxicity, so the linking agent residual quantity must be up to standard in the product.The linking agent residual quantity can not be higher than 2 μ g/g in the regulation gel, by data in the table as can be known, when crosslinker concentration was low, it was below the mark directly by washing the linking agent residual quantity to be dropped to, but when improving crosslinker concentration, the washing effect can not be up to standard, therefore we combine with the High Temperature High Pressure distillation method, can remove residual cross-linker in the gel significantly, thereby it are better to obtain biocompatibility, toxicity is lower, is applicable to that soft tissue is filled or the hydrogel material of tissue repair.
It is cited that content of the present invention is not limited to embodiment, and the conversion of any equivalence that those of ordinary skills take technical solution of the present invention by reading specification sheets of the present invention is claim of the present invention and contains.
Claims (8)
1. the preparation method of injection hyaluronic acid-collagen protein composite aquogel is characterized in that:
Realized by following steps:
Step 1: hyaluronate sodium is dissolved in the basic solution, stirs it is dissolved fully, make that hyaluronic mass concentration is 6%-20% in the mixing solutions;
Step 2: add collagen protein, making the mass concentration of collagen protein in the mixing solutions is 1-6%, stirs;
Step 3: add linking agent, the mass concentration that makes linking agent in the mixing solutions is 1-10%, temperature of reaction 30-60 ℃, and reaction times 1-14 hour;
Step 4: remove residual cross-linker;
Step 5: the product that obtains in physiological saline balance 3-6 hour;
Step 6: the centrifugal physiological saline of removing, products therefrom is pulverized the formation particle.
2. the preparation method of a kind of injection hyaluronic acid according to claim 1-collagen protein composite aquogel is characterized in that:
In the step 1, the molecular weight of hyaluronate sodium is 50-300 ten thousand.
3. the preparation method of a kind of injection hyaluronic acid according to claim 1 and 2-collagen protein composite aquogel is characterized in that:
In the step 1, basic solution is selected from sodium hydroxide, potassium hydroxide, sodium carbonate solution, and the molecular volume mark is 0.02-2 mol/L.
4. the preparation method of a kind of injection hyaluronic acid according to claim 3-collagen protein composite aquogel is characterized in that:
In the step 2, collagen protein is selected from total length collagen protein, collagen polypeptide, the gelatin that extracts from animal tissues; Or the recombined collagen, the Human-like Collagen that adopt gene engineering method to produce.
5. the preparation method of a kind of injection hyaluronic acid according to claim 4-collagen protein composite aquogel is characterized in that:
In the step 3, linking agent is selected from ethylene glycol diglycidylether, 1,4-butanediol diglycidyl ether, glycol ether diglycidylether, polyethyleneglycol diglycidylether, polypropylene glycol diglycidyl ether, 1,6-hexanediol diglycidyl ether, 1,2,7,8-diepoxy octane, divinylsulfone.
6. according to the preparation method of a kind of injection hyaluronic acid-collagen protein composite aquogel described in the claim 5, it is characterized in that:
In the step 4, the method for removing residual cross-linker is selected from washing, organic solvent cleaning, High Temperature High Pressure distillation.
7. the preparation method of a kind of injection hyaluronic acid according to claim 6-collagen protein composite aquogel is characterized in that:
In the step 6, pulverization process is selected from extruding, grinding, cutting mode.
8. injection hyaluronic acid-collagen protein composite aquogel that preparation method as claimed in claim 1 makes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102640629A CN103333349A (en) | 2013-06-28 | 2013-06-28 | Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102640629A CN103333349A (en) | 2013-06-28 | 2013-06-28 | Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103333349A true CN103333349A (en) | 2013-10-02 |
Family
ID=49241563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102640629A Pending CN103333349A (en) | 2013-06-28 | 2013-06-28 | Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103333349A (en) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104327311A (en) * | 2014-10-27 | 2015-02-04 | 天津科技大学 | Hyaluronic acid composite cross-linked hydrogel and preparation method thereof |
| CN105504313A (en) * | 2016-01-22 | 2016-04-20 | 杭州协合医疗用品有限公司 | Preparation method and application of hyaluronic acid plural gel |
| CN106053369A (en) * | 2016-07-13 | 2016-10-26 | 浙江景嘉医疗科技有限公司 | Method for detecting content of free sodium hyaluronate in medical cross-linking sodium hyaluronate gel |
| CN106176292A (en) * | 2016-07-16 | 2016-12-07 | 江苏华亿美素生物组织工程有限公司 | A kind of biodegradable injection molding process decorative material and preparation method thereof |
| CN107189119A (en) * | 2017-07-24 | 2017-09-22 | 苏州景卓生物技术有限公司 | A kind of preparation method and applications of compound sodium hyaluronate collagen hydrogels |
| CN108892411A (en) * | 2018-07-11 | 2018-11-27 | 俞小峰 | A kind of preparation method of concrete waterproofer |
| CN109078219A (en) * | 2018-08-15 | 2018-12-25 | 白晋 | A kind of preparation method for the autologous collagen albumen tissue filler cooperating facial line engraving |
| CN109200338A (en) * | 2018-08-15 | 2019-01-15 | 白晋 | A kind of preparation method of the autologous collagen protein gel with sodium hyaluronate |
| CN110713727A (en) * | 2018-06-27 | 2020-01-21 | 中国科学院过程工程研究所 | Collagen hydrogel prepared at low temperature, preparation method and application thereof |
| CN112587721A (en) * | 2020-12-30 | 2021-04-02 | 广州益诚生物科技有限公司 | Injection filling material and preparation process thereof |
| CN112980001A (en) * | 2021-03-16 | 2021-06-18 | 杭州基智生物科技有限公司 | Collagen composite hyaluronic acid gel, extracellular matrix bionic material and preparation method |
| CN113842502A (en) * | 2021-09-29 | 2021-12-28 | 西安德诺海思医疗科技有限公司 | Injection filler containing deproteinized bone and preparation method thereof |
| CN113952510A (en) * | 2021-11-09 | 2022-01-21 | 无锡本物医疗器械有限公司 | Targeted injection type filler composition and preparation method and application thereof |
| CN114146223A (en) * | 2021-12-10 | 2022-03-08 | 三亚悦美科技有限公司 | Recombinant collagen compound injection and preparation method thereof |
| CN114163667A (en) * | 2021-12-07 | 2022-03-11 | 华熙生物科技股份有限公司 | Cross-linked gel for isolation, preparation method and application |
| CN114225118A (en) * | 2021-12-27 | 2022-03-25 | 深圳齐康医疗器械有限公司 | Injectable artificial dermis for promoting wound healing and preparation method and application thereof |
| CN114272362A (en) * | 2021-12-30 | 2022-04-05 | 西安德诺海思医疗科技有限公司 | A kind of recombinant protein freeze-dried powder injection for injection and preparation method thereof |
| CN114470333A (en) * | 2022-03-09 | 2022-05-13 | 哈尔滨敷尔佳科技股份有限公司 | Preparation method of crosslinked recombinant collagen gel |
| CN114931666A (en) * | 2022-06-09 | 2022-08-23 | 海雅美生物技术(珠海)有限公司 | Preparation method of hyaluronic acid-collagen composite cross-linked microspheres for facial filling |
| CN115721778A (en) * | 2022-12-15 | 2023-03-03 | 西安德诺海思医疗科技有限公司 | Collagen/hyaluronic acid composite gel for skin injection and preparation method thereof |
| US11684700B2 (en) | 2014-08-15 | 2023-06-27 | The Johns Hopkins University | Composite material for tissue restoration |
| WO2023125686A1 (en) * | 2021-12-28 | 2023-07-06 | Shanghai Qisheng Biological Preparation Co., Ltd. | Soft tissue augmentation using injectable, neutral ph soluble collagen-glycosaminoglycan compositions |
| US11771807B2 (en) | 2018-05-09 | 2023-10-03 | The Johns Hopkins University | Nanofiber-hydrogel composites for cell and tissue delivery |
| US12036339B2 (en) | 2018-05-09 | 2024-07-16 | The Johns Hopkins University | Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| CN101264348A (en) * | 2008-05-19 | 2008-09-17 | 山东凯乐普生物工程有限公司 | Preparation technique of sodium hyaluronate gel granule |
-
2013
- 2013-06-28 CN CN2013102640629A patent/CN103333349A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| CN101264348A (en) * | 2008-05-19 | 2008-09-17 | 山东凯乐普生物工程有限公司 | Preparation technique of sodium hyaluronate gel granule |
Non-Patent Citations (2)
| Title |
|---|
| TATIANA SEGURA ET AL.: ""Crosslinked hyaluronic acid hydrogels: a strategy to functionalize and pattern"", 《BIOMATERIALS》, vol. 26, 28 February 2005 (2005-02-28), pages 359 - 371 * |
| 王海燕等: ""生物性注射美容材料的研究进展"", 《食品与药品》, vol. 14, no. 2, 10 March 2012 (2012-03-10) * |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11684700B2 (en) | 2014-08-15 | 2023-06-27 | The Johns Hopkins University | Composite material for tissue restoration |
| US11707553B2 (en) | 2014-08-15 | 2023-07-25 | The Johns Hopkins University | Composite material for tissue restoration |
| CN104327311B (en) * | 2014-10-27 | 2017-06-06 | 天津科技大学 | A kind of hyaluronic acid composite crosslinking hydrogel and preparation method thereof |
| CN104327311A (en) * | 2014-10-27 | 2015-02-04 | 天津科技大学 | Hyaluronic acid composite cross-linked hydrogel and preparation method thereof |
| CN105504313A (en) * | 2016-01-22 | 2016-04-20 | 杭州协合医疗用品有限公司 | Preparation method and application of hyaluronic acid plural gel |
| CN105504313B (en) * | 2016-01-22 | 2018-06-19 | 杭州协合医疗用品有限公司 | A kind of preparation method and applications of hyaluronic acid plural gel |
| CN106053369A (en) * | 2016-07-13 | 2016-10-26 | 浙江景嘉医疗科技有限公司 | Method for detecting content of free sodium hyaluronate in medical cross-linking sodium hyaluronate gel |
| CN106176292A (en) * | 2016-07-16 | 2016-12-07 | 江苏华亿美素生物组织工程有限公司 | A kind of biodegradable injection molding process decorative material and preparation method thereof |
| CN107189119B (en) * | 2017-07-24 | 2020-06-16 | 浙江景嘉医疗科技有限公司 | Preparation method and application of composite hyaluronic acid collagen hydrogel |
| CN107189119A (en) * | 2017-07-24 | 2017-09-22 | 苏州景卓生物技术有限公司 | A kind of preparation method and applications of compound sodium hyaluronate collagen hydrogels |
| US12161781B2 (en) | 2018-05-09 | 2024-12-10 | The Johns Hopkins University | Nanofiber-hydrogel composites for cell and tissue delivery |
| US11771807B2 (en) | 2018-05-09 | 2023-10-03 | The Johns Hopkins University | Nanofiber-hydrogel composites for cell and tissue delivery |
| US12036339B2 (en) | 2018-05-09 | 2024-07-16 | The Johns Hopkins University | Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration |
| CN110713727A (en) * | 2018-06-27 | 2020-01-21 | 中国科学院过程工程研究所 | Collagen hydrogel prepared at low temperature, preparation method and application thereof |
| CN108892411A (en) * | 2018-07-11 | 2018-11-27 | 俞小峰 | A kind of preparation method of concrete waterproofer |
| CN109200338A (en) * | 2018-08-15 | 2019-01-15 | 白晋 | A kind of preparation method of the autologous collagen protein gel with sodium hyaluronate |
| CN109078219A (en) * | 2018-08-15 | 2018-12-25 | 白晋 | A kind of preparation method for the autologous collagen albumen tissue filler cooperating facial line engraving |
| CN112587721A (en) * | 2020-12-30 | 2021-04-02 | 广州益诚生物科技有限公司 | Injection filling material and preparation process thereof |
| CN112980001B (en) * | 2021-03-16 | 2024-03-19 | 杭州基智生物科技有限公司 | Collagen composite hyaluronic acid gel, extracellular matrix bionic material and preparation method |
| CN112980001A (en) * | 2021-03-16 | 2021-06-18 | 杭州基智生物科技有限公司 | Collagen composite hyaluronic acid gel, extracellular matrix bionic material and preparation method |
| CN113842502A (en) * | 2021-09-29 | 2021-12-28 | 西安德诺海思医疗科技有限公司 | Injection filler containing deproteinized bone and preparation method thereof |
| CN113952510A (en) * | 2021-11-09 | 2022-01-21 | 无锡本物医疗器械有限公司 | Targeted injection type filler composition and preparation method and application thereof |
| CN114163667B (en) * | 2021-12-07 | 2024-02-13 | 华熙生物科技股份有限公司 | Cross-linked gel for isolation, preparation method and application |
| CN114163667A (en) * | 2021-12-07 | 2022-03-11 | 华熙生物科技股份有限公司 | Cross-linked gel for isolation, preparation method and application |
| CN114146223A (en) * | 2021-12-10 | 2022-03-08 | 三亚悦美科技有限公司 | Recombinant collagen compound injection and preparation method thereof |
| CN114225118A (en) * | 2021-12-27 | 2022-03-25 | 深圳齐康医疗器械有限公司 | Injectable artificial dermis for promoting wound healing and preparation method and application thereof |
| WO2023125686A1 (en) * | 2021-12-28 | 2023-07-06 | Shanghai Qisheng Biological Preparation Co., Ltd. | Soft tissue augmentation using injectable, neutral ph soluble collagen-glycosaminoglycan compositions |
| CN114272362A (en) * | 2021-12-30 | 2022-04-05 | 西安德诺海思医疗科技有限公司 | A kind of recombinant protein freeze-dried powder injection for injection and preparation method thereof |
| CN114470333A (en) * | 2022-03-09 | 2022-05-13 | 哈尔滨敷尔佳科技股份有限公司 | Preparation method of crosslinked recombinant collagen gel |
| WO2023236326A1 (en) * | 2022-06-09 | 2023-12-14 | 海雅美生物技术(珠海)有限公司 | Method for preparing hyaluronic acid-collagen composite cross-linked microspheres for face filling |
| CN114931666A (en) * | 2022-06-09 | 2022-08-23 | 海雅美生物技术(珠海)有限公司 | Preparation method of hyaluronic acid-collagen composite cross-linked microspheres for facial filling |
| CN115721778A (en) * | 2022-12-15 | 2023-03-03 | 西安德诺海思医疗科技有限公司 | Collagen/hyaluronic acid composite gel for skin injection and preparation method thereof |
| CN115721778B (en) * | 2022-12-15 | 2025-05-13 | 西安德诺海思医疗科技有限公司 | A collagen/hyaluronic acid composite gel for skin injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103333349A (en) | Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof | |
| JP2023182726A (en) | Combination with cross-linked hyaluronic acid and PRP/BMC | |
| CN1829743B (en) | Complex matrix for biomedical use | |
| Geng et al. | Hierarchically designed injectable hydrogel from oxidized dextran, amino gelatin and 4-arm poly (ethylene glycol)-acrylate for tissue engineering application | |
| CN104086788B (en) | A kind of injection modifies hyaluronic acid sodium gel | |
| Qin et al. | Methacrylated pullulan/polyethylene (glycol) diacrylate composite hydrogel for cartilage tissue engineering | |
| CN102863631B (en) | Cross-linked sodium hyaluronate gel for tissue filler for plastic surgery and method for preparing cross-linked sodium hyaluronate gel | |
| EP4063433B1 (en) | Hydrogel of mercapto-modified macromolecular compound, and preparation method therefor and use thereof | |
| Liu et al. | A simple yet effective hydrogel dressing for advanced microenvironmental management of diabetic wounds with intrinsic regulation | |
| CN101244290A (en) | Method for preparing crosslinked hyaluronic acid microgel for tissue filling | |
| US20100190704A1 (en) | Structure comprising chitosan and collagen | |
| CN106279729A (en) | A kind of cross-linking hyaluronic acid gel and preparation method and application | |
| CN102836465A (en) | Silk-fibroi and hyaluronic-acid (HA) composite gel for injection and preparation and application thereof | |
| EP2861626A1 (en) | Method of preparing a composition based on hyaluronic acid | |
| US20240131222A1 (en) | Transdermal photocuring forming hydrogel with biological activity as well as a preparation method and an application thereof | |
| CN110404055A (en) | Pharmaceutical composition comprising collagen and Sodium Hyaluronate | |
| CN115671405B (en) | Joint cavity injection gel and preparation method thereof | |
| CN114099787A (en) | Absorbable biological membrane, preparation method and application thereof | |
| CN115068688A (en) | Absorbable face filling material and preparation method and application thereof | |
| CN105860151A (en) | High-molecular pulullan polysaccharide-collagen composite hydrogel for injection, and preparation method thereof | |
| CN116159192B (en) | Injectable hemostatic anti-adhesion hydrogel and preparation method thereof | |
| CN117838928A (en) | Solution for tissue filling and preparation method and application thereof | |
| CN106714856B (en) | Composition containing glycosaminoglycan and protein | |
| Paul | Gelatin-methacryloyl-chitosan (GelMA-CS) hydrogel: a novel orthopaedic bioadhesive | |
| CN105624245B (en) | Modification method of collagen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131002 |